<DOC>
	<DOCNO>NCT02705300</DOCNO>
	<brief_summary>Treatment FOLFOXIRI ( 5-fluorouracil , oxaliplatin , irinotecan ) effective , serious side effect , may require hospitalization . The purpose study investigate whether addition tocotrienol reduce side effect FOLFOXIRI otherwise lead hospitalization .</brief_summary>
	<brief_title>Side Effects FOLFOXIRI + Tocotrienol/Placebo First Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<criteria>Histologically cytologically verify colorectal adenocarcinoma . Patients receive first line treatment metastatic disease , include potentially resectable nonresectable disease &gt; 6 month without recurrence end adjuvant chemotherapy radically treat stage II III colorectal cancer Disease evaluable accord RECIST 1.1 , necessarily measurable disease . Age 1875 year Performance status ( PS ) 01 . If age 7175 , PS 0 Life expectancy &gt; 3 month Organ bone marrow function follow : Neutrophil count ≥ 1.5 x 10^9/L Thrombocytes ≥ 100 x 10^9/L Total bilirubin ≤ 1.5 x upper level normal ( ULN ) Alanine transaminase ( ALAT ) ≤ 2.5 x ULN ( or≤ 5 x ULN case liver metastasis ) Fertile woman must present negative pregnancy test . Male ( female fertile partner ) well female patient must use secure contraceptive 6 month end treatment . Orally write informed consent treatment biobank Primarily resectable metastasis Chemotherapy , radiotherapy immunotherapy within 4 week Known neuropathy ≥ grade 2 Serious competitive medical condition Other concurrent malignant disease nonmelanoma skin cancer Previous serious unexpected reaction 5fluorouracil , calcium folinate , oxaliplatin , irinotecan capecitabine . Hypersensitivity one active substance auxilliary agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>